search
Back to results

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. (DUAL™ I Japan)

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
insulin degludec/liraglutide
insulin degludec
liraglutide
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female Japanese subjects, age at least 20 years at the time of signing informed consent
  • Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening
  • HbA1c (glycosylated haemoglobin) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. When approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a HbA1c below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%
  • Body-mass index (BMI) above or equal to 20 kg/m^2
  • Subjects on stable therapy with one OAD (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-GI, TZD, SU, SGLT2i or glinide) prior to screening according to approved Japanese labelling

Exclusion Criteria:

  • Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes)
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening
  • Anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism
  • Impaired liver function, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or above 2.5 times upper limit of normal
  • Renal impairment estimated Glomerular Filtration Rate (eGFR) below 60mL/min/1.73m^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • Screening calcitonin equal to or above 50 ng/L
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Subjects presently classified as being in New York Heart Association (NYHA) Class IV

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Insulin degludec/liraglutide OD

Insulin degludec OD

Liraglutide OD

Arm Description

Outcomes

Primary Outcome Measures

Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).

Secondary Outcome Measures

Change From Baseline in Body Weight (kg)
Change from baseline (week 0) in body weight after 52 weeks of treatment.
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG after 52 weeks
Insulin Dose
Actual daily total insulin dose after 52 weeks of treatment.
Responder (Yes/no): HbA1c Less Than 7.0%
Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero
Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Responder (Yes/no): HbA1c Less Than 6.5%
Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero
Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.
Responder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Change in Waist Circumference
Change from baseline (week 0) in waist circumference after 52 weeks of treatment.
Change in Blood Pressure (Systolic and Diastolic)
Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.
Self-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
Change in SMBG 9-point Profile - Mean of the 9-point Profile
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
Total Cholesterol as a Ratio to Baseline at 52 Weeks
Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks
High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Triglycerides as a Ratio to Baseline at 52 Weeks
Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Free Fatty Acids as a Ratio to Baseline at 52 Weeks
Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Fasting C-peptide as a Ratio to Baseline at 52 Weeks
Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Fasting Human Insulin as a Ratio to Baseline at 52 Weeks
Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Fasting Glucagon as a Ratio to Baseline at 52 Weeks
Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Proinsulin as a Ratio to Baseline at 52 Weeks
Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Number of Treatment Emergent Adverse Events (TEAEs)
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: Severe hypoglycaemia Documented symptomatic hypoglycaemia Asymptomatic hypoglycaemia Probable symptomatic hypoglycaemia Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
Anti-drug Antibodies: Anti-insulin Degludec Antibodies
Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound & precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.
Anti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies
Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.
Change in Clinical Evaluation: Electrocardiogram (ECG)
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.
Change in Clinical Evaluation: Pulse
Change in pulse after 52 weeks of treatment.
Serum Concentrations of Insulin Degludec
Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.
Plasma Concentrations of Liraglutide
Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.

Full Information

First Posted
November 16, 2015
Last Updated
March 10, 2021
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT02607306
Brief Title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Acronym
DUAL™ I Japan
Official Title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
November 18, 2015 (Actual)
Primary Completion Date
December 15, 2017 (Actual)
Study Completion Date
December 22, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
819 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Insulin degludec/liraglutide OD
Arm Type
Experimental
Arm Title
Insulin degludec OD
Arm Type
Active Comparator
Arm Title
Liraglutide OD
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
insulin degludec/liraglutide
Intervention Description
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Intervention Type
Drug
Intervention Name(s)
insulin degludec
Intervention Description
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Intervention Type
Drug
Intervention Name(s)
liraglutide
Intervention Description
Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
Description
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).
Time Frame
Week 0, Week 52
Secondary Outcome Measure Information:
Title
Change From Baseline in Body Weight (kg)
Description
Change from baseline (week 0) in body weight after 52 weeks of treatment.
Time Frame
Week 0, Week 52
Title
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Description
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time Frame
Weeks 0-52
Title
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg
Description
Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.
Time Frame
Week 0, Week 52
Title
Change From Baseline in Fasting Plasma Glucose (FPG)
Description
Change from baseline (week 0) in FPG after 52 weeks
Time Frame
Week 0, Week 52
Title
Insulin Dose
Description
Actual daily total insulin dose after 52 weeks of treatment.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 7.0%
Description
Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero
Description
Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Description
Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Description
Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 6.5%
Description
Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero
Description
Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
Description
Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time Frame
After 52 weeks of treatment
Title
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Description
Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time Frame
After 52 weeks of treatment
Title
Change in Waist Circumference
Description
Change from baseline (week 0) in waist circumference after 52 weeks of treatment.
Time Frame
Week 0, Week 52
Title
Change in Blood Pressure (Systolic and Diastolic)
Description
Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.
Time Frame
Week 0, Week 52
Title
Self-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)
Description
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
Time Frame
After 52 weeks of the treatment
Title
Change in SMBG 9-point Profile - Mean of the 9-point Profile
Description
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
Time Frame
Week 0, week 52
Title
Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)
Description
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
Time Frame
Week 0, week 52
Title
Total Cholesterol as a Ratio to Baseline at 52 Weeks
Description
Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Description
Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Description
High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks
Description
Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Triglycerides as a Ratio to Baseline at 52 Weeks
Description
Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Free Fatty Acids as a Ratio to Baseline at 52 Weeks
Description
Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Fasting C-peptide as a Ratio to Baseline at 52 Weeks
Description
Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Fasting Human Insulin as a Ratio to Baseline at 52 Weeks
Description
Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Fasting Glucagon as a Ratio to Baseline at 52 Weeks
Description
Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Proinsulin as a Ratio to Baseline at 52 Weeks
Description
Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.
Time Frame
After 52 weeks of treatment
Title
Number of Treatment Emergent Adverse Events (TEAEs)
Description
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Time Frame
0-52 weeks
Title
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Description
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time Frame
0-52 weeks
Title
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Description
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time Frame
0-52 weeks
Title
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
Description
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: Severe hypoglycaemia Documented symptomatic hypoglycaemia Asymptomatic hypoglycaemia Probable symptomatic hypoglycaemia Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
Time Frame
0-52 weeks
Title
Anti-drug Antibodies: Anti-insulin Degludec Antibodies
Description
Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound & precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.
Time Frame
at week 52
Title
Anti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies
Description
Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.
Time Frame
at week 52
Title
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
Description
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.
Time Frame
at screening (week -2 to week 0), at week 52
Title
Change in Clinical Evaluation: Electrocardiogram (ECG)
Description
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.
Time Frame
at screening (week -2 to week 0), at week 52
Title
Change in Clinical Evaluation: Pulse
Description
Change in pulse after 52 weeks of treatment.
Time Frame
Week 0, week 52
Title
Serum Concentrations of Insulin Degludec
Description
Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.
Time Frame
Weeks 2, 8, 16, 26, 44, 52
Title
Plasma Concentrations of Liraglutide
Description
Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.
Time Frame
Weeks 2, 8, 16, 26, 44, 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female Japanese subjects, age at least 20 years at the time of signing informed consent Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening HbA1c (glycosylated haemoglobin) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. When approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a HbA1c below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3% Body-mass index (BMI) above or equal to 20 kg/m^2 Subjects on stable therapy with one OAD (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-GI, TZD, SU, SGLT2i or glinide) prior to screening according to approved Japanese labelling Exclusion Criteria: Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes) Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening Anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism Impaired liver function, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or above 2.5 times upper limit of normal Renal impairment estimated Glomerular Filtration Rate (eGFR) below 60mL/min/1.73m^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Screening calcitonin equal to or above 50 ng/L History of pancreatitis (acute or chronic) Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) Subjects presently classified as being in New York Heart Association (NYHA) Class IV
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Adachi-ku, Tokyo
ZIP/Postal Code
123-0845
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Akita-shi, Akita
ZIP/Postal Code
010-8543
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Annaka-shi, Gunma
ZIP/Postal Code
379-0116
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Asahikawa-shi, Hokkaido
ZIP/Postal Code
070-0002
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chiba-shi, Chiba
ZIP/Postal Code
260-0804
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chitose, Hokkaido
ZIP/Postal Code
066-0032
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chuo-ku, Tokyo
ZIP/Postal Code
103-0002
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chuo-ku,Tokyo
ZIP/Postal Code
103-0025
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Chuo-ku,
ZIP/Postal Code
104 0061
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Edogawa-ku, Tokyo
ZIP/Postal Code
134-0084
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Fujisawa-shi, Kanagawa
ZIP/Postal Code
251-0041
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Fukuoka-shi, Fukuoka
ZIP/Postal Code
819-0168
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Fukushima
ZIP/Postal Code
963-8851
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Gunma
ZIP/Postal Code
373-0036
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Hachioji-shi, Tokyo
ZIP/Postal Code
192-0917
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Hokkaido
ZIP/Postal Code
060-0062
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Hokkaido
ZIP/Postal Code
078-8236
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Ibaraki
ZIP/Postal Code
311-0113
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Ichihara-shi, Chiba
ZIP/Postal Code
290-0003
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Iruma-shi, Saitama
ZIP/Postal Code
358-0011
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Itabashi-ku, Tokyo
ZIP/Postal Code
173-0004
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Itabashi-ku, Tokyo
ZIP/Postal Code
175-0093
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Izumisano-shi,Osaka
ZIP/Postal Code
598-8577
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Izumisano-shi
ZIP/Postal Code
598 0048
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kagoshima-shi, Kagoshima
ZIP/Postal Code
890-0061
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kamakura-shi
ZIP/Postal Code
247 0056
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kanagawa
ZIP/Postal Code
235-0045
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kanra-gun, Gunma
ZIP/Postal Code
370-2214
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kashiwara-shi, Osaka
ZIP/Postal Code
582-0005
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kawagoe-shi, Saitama
ZIP/Postal Code
350-0851
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kawaguchi-shi, Saitama
ZIP/Postal Code
332-0012
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kawasaki-shi,Kanagawa
ZIP/Postal Code
215-0026
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kisarazu-shi, Chiba
ZIP/Postal Code
292-0038
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kobe-shi, Hyogo
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kuki-shi, Saitama
ZIP/Postal Code
346-8530
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kumamoto-shi, Kumamoto
ZIP/Postal Code
860-0811
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kumamoto-shi, Kumamoto
ZIP/Postal Code
861-8039
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kumamoto
ZIP/Postal Code
862-0976
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kushiro-shi, Hokkaido
ZIP/Postal Code
085-0032
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Kyoto-shi, Kyoto
ZIP/Postal Code
606-8507
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Minato-ku, Tokyo
ZIP/Postal Code
108-0075
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Mito-shi, Ibaraki
ZIP/Postal Code
310-0826
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Mito-shi, Ibaraki
ZIP/Postal Code
311-4153
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Miura-shi, Kanagawa
ZIP/Postal Code
238-0101
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Miyazaki
ZIP/Postal Code
880-0034
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Nagoya-shi, Aichi
ZIP/Postal Code
455-8530
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Nagoya-shi, Aichi
ZIP/Postal Code
456-0058
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Nishinomiya-shi, Hygo
ZIP/Postal Code
662 0971
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Obihiro-shi, Hokkaido
ZIP/Postal Code
080 0016
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Obihiro-shi, Hokkaido
ZIP/Postal Code
080 0848
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Oita-shi
ZIP/Postal Code
870 0039
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Okawa-shi, Fukuoka
ZIP/Postal Code
831-0016
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Onga-gun, Fukuoka
ZIP/Postal Code
811-4342
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Osaka-shi, Osaka
ZIP/Postal Code
530-0013
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Osaka-shi, Osaka
ZIP/Postal Code
533-0024
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Osaka-shi, Osaka
ZIP/Postal Code
536-0001
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Osaka
ZIP/Postal Code
569-1045
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Ota-ku, Tokyo
ZIP/Postal Code
1430015
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Saijo-shi, Ehime
ZIP/Postal Code
793-0027
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sapporo-shi, Hokkaido
ZIP/Postal Code
004-0004
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sapporo-shi, Hokkaido
ZIP/Postal Code
060-0001
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sendai-shi, Miyagi
ZIP/Postal Code
980-0011
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Sendai-shi, Miyagi
ZIP/Postal Code
980-0021
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Shimotsuke-shi, Tochigi
ZIP/Postal Code
329-0433
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Shizuoka-shi, Shizuoka
ZIP/Postal Code
424-0853
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tochigi
ZIP/Postal Code
323-0022
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
103-0028
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
104-0031
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
169-0073
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Toshima-ku, Tokyo
ZIP/Postal Code
171-0021
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Toyonaka-shi, Osaka
ZIP/Postal Code
560-0082
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Ube-shi, Yamaguchi
ZIP/Postal Code
755-0046
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Urasoe-shi,
ZIP/Postal Code
901 2104
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Yamaguchi-shi, Yamaguchi
ZIP/Postal Code
754-0002
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Yamato-shi, Kanagawa
ZIP/Postal Code
242-0004
Country
Japan

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Citations:
PubMed Identifier
31407845
Citation
Kaku K, Araki E, Tanizawa Y, Ross Agner B, Nishida T, Ranthe M, Inagaki N. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes Obes Metab. 2019 Dec;21(12):2674-2683. doi: 10.1111/dom.13856. Epub 2019 Aug 28.
Results Reference
result
PubMed Identifier
33595901
Citation
Komatsu M, Watada H, Kaneko S, Ross Agner BF, Nishida T, Kaku K. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. J Diabetes Investig. 2021 Sep;12(9):1610-1618. doi: 10.1111/jdi.13525. Epub 2021 Mar 24.
Results Reference
result
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

We'll reach out to this number within 24 hrs